Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
From Bufo Toad Venom to Big Pharma
Research on synthetic 5-MeO-DMT has advanced from early observational studies to positive clinical trials. Scientists have moved from natural toad secretions to standardized 5-MeO-DMT pharmaceutical formulations. Major questions remain regarding…
Gland Pharma gets U.S. FDA nod for Sugammadex injection
Shares of Gland Pharma were in the spotlight on Tuesday, rising more than 4%, after the Hyderabad-based generic injectable drugmaker got the U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug application for Sugammadex…
'It is okay not to be okay': NFL legend Terrell Davis joins growing roster of athletes partnering with big pharma to raise health awareness
For decades, pharmaceutical advertising largely revolved around television commercials urging patients to ask their doctors about branded medication. Increasingly, however, drugmakers are investing in a different kind of marketing…
NewAmsterdam Pharma (NAMS) Projected to Announce Earnings on Wednesday
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) is projected to issue its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of ($0.48) per share and revenue of $1.8770 million for the…
Royalty Pharma (RPRX) Projected to Release Earnings on Wednesday
Royalty Pharma (NASDAQ:RPRX - Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to announce earnings of $1.27 per share and revenue of $758.9270 million…
Urogen Pharma (NASDAQ:URGN) Receives Average Rating of 'Moderate Buy' from Analysts
Urogen Pharma (NASDAQ:URGN - Get Free Report) has been assigned an average rating of 'Moderate Buy' from the ten research firms that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock…
Entropy Technologies LP Cuts Stock Holdings in Royalty Pharma PLC $RPRX
Entropy Technologies LP lowered its stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 79.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor…
ADAR1 Capital Management LLC Boosts Stock Position in Urogen Pharma $URGN
ADAR1 Capital Management LLC raised its holdings in Urogen Pharma (NASDAQ:URGN - Free Report) by 139.1% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 395,459 shares of the…
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year High - What's Next?
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report)'s stock price hit a new 52-week high during trading on Wednesday. The stock traded as high as $60.08 and last traded at $59.97, with a volume of 3138526 shares trading hands. The stock had…
19,254 Shares in Royalty Pharma PLC $RPRX Bought by Lido Advisors LLC
Lido Advisors LLC bought a new stake in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 19,254 shares of the…
First Trust Advisors LP Raises Stock Holdings in BridgeBio Pharma, Inc. $BBIO
First Trust Advisors LP boosted its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 20.7% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 339,907 shares…
Ally Bridge Group NY LLC Purchases Shares of 202,124 Urogen Pharma $URGN
Ally Bridge Group NY LLC acquired a new stake in shares of Urogen Pharma (NASDAQ:URGN - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 202,124…
Spyglass Capital Management LLC Has $84.17 Million Position in Ascendis Pharma A/S $ASND
Spyglass Capital Management LLC trimmed its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) by 11.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional…
ICON Public Limited Company (ICLR) Surges on Net Book-to-Bill Strength
Harris Oakmark recently released its second-quarter 2026 investor letter for the 'Oakmark U.S. Concentrated Strategy'. A copy of the letter can be downloaded here. The strategy returned 9.21% (net) in the second quarter, lagging the Russell 1000…
Brazil approves generic GLP-1 drug sold by Swiss firm Sandoz
According to the statement, the Brazilian medicines regulator Anvisa has authorised the product Owozy for the treatment of type 2 diabetes. The product is being developed by Adalvo and will be marketed by Sandoz in Brazil. The market launch is…
Receive a Daily briefing on Pharma Industry News
Get Started